Current scenario of drug development for leishmaniasis

Indian Journal of Medical Research

Volumn 123, Issue 3, 2006, Pages 399-410

  Croft, Simon L ^a   Seifert, Karin ^b   Yardley, Vanessa ^b  

^a Drugs for Neglected Diseases Initiative DNDi   (Switzerland)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Amphotericin B; Cutaneous leishmaniasis; First line drugs; Miltefosine; Toxicity; Visceral leishmaniasis

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTILEISHMANIAL AGENT; ANTIMONY DERIVATIVE; ANTIPROTOZOAL AGENT; ARABINOGALACTAN; BISPHOSPHONIC ACID DERIVATIVE; FLUCONAZOLE; GENTAMICIN; IMIQUIMOD; ITRACONAZOLE; KETOCONAZOLE; LICOCHALCONE A; MAESABALIDE; MEGLUMINE ANTIMONATE; METHYLBENZETHONIUM CHLORIDE; MILTEFOSINE; PAMIDRONIC ACID; PAROMOMYCIN; PENTAMIDINE; PHOSPHORYLCHOLINE; PLANT MEDICINAL PRODUCT; POSACONAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RISEDRONIC ACID; SITAMAQUINE; STIBOGLUCONATE SODIUM; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREA;

AMASTIGOTE; CLINICAL TRIAL; DRUG COST; DRUG HALF LIFE; DRUG STRUCTURE; DRUG SYNTHESIS; GENETIC TRANSFECTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; METHEMOGLOBINEMIA; NON INVASIVE MEASUREMENT; NONHUMAN; PROMASTIGOTE; REVIEW; SKIN IRRITATION; SKIN LEISHMANIASIS; TERATOGENICITY; UNSPECIFIED SIDE EFFECT; VISCERAL LEISHMANIASIS;

AMPHOTERICIN B; ANIMALS; ANTIPROTOZOAL AGENTS; DRUG DESIGN; HUMANS; LEISHMANIA; LEISHMANIASIS; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, VISCERAL; MODELS, CHEMICAL; PAROMOMYCIN; PHOSPHORYLCHOLINE;

EID: 33745196673     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial." BMJ 2001; 323 : 419-22.
2. WHO. The Leishmaniases and Leishmania/HIV co-infections. Geneva: WHO/ OMS; 1998.
3. Dereure J, Thanh HD, Lavabre-Bertrand T, Cartron G, Bastides F, Richard-Lenoble D, et al. Visceral leishmaniasis. Persistence of parasites in lymph nodes after clinical cure. J Infect 2003; 47 : 77-81.
4. Pagliano P, Rossi M, Rescigno C, Altieri S, Coppola MG, Gramiccia M, et al. Mediterranean visceral leishmaniasis in HIV-negative adults: a retrospective analysis of 64 consecutive cases (1995-2001). J Antimicrob Chemother 2003; 52 : 264-8.
5. Mira JA, Corzo JE, Rivero A, Macias J, De Leon FL, Torre-Cisneros J, et al. Frequency of visceral leishmaniasis relapses in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy. Am J Trop Med Hyg 2004; 70 : 298-301.
6. Croft SL, Coombs GH. Leishmaniasis- current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 2003; 19 : 502-8.
7. Croft SL, Neal RA, Pendergast W, Chan JH. The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani. Biochem Pharmacol 1987; 36 : 2633-6.
8. Kuhlencord A, Maniera T, Eibl H, Unger C. Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob Agents Chemother 1992; 36 : 1630-4.
9. Croft SL, Snowdon D, Yardley V. The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J Antimicrob Chemother 1996; 38 : 1041-7.
10. Bryceson A. A policy for leishmaniasis with respect to the prevention and control of drug resistance. Trop Med Int Health 2001; 6 : 928-34.
11. Seifert K, Matu S, Javier Perez-Victoria F, Castanys S, Gamarro F, Croft SL. Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine). Int J Antimicrob Agents 2003; 22 : 380-7.
12. Perez-Victoria FJ, Gamarro F, Ouellette M, Castanys S. Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance. J Biol Chem 2003; 278 : 49965-71.
13. Escobar P, Matu S, Marques C, Croft SL. Sensitivities of Leishmania species to hexadecylphophocholine (miltefosine), ET-18-OCH3 (edelfosine) and amphotericin B. Acta Trop 2002; 81 : 151-7.
14. Yardley V, Croft SL, De Doncker S, Dujardin JC, Koirala S, Rijal S, et al. The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine. Am J Trop Med Hyg 2005; 73 : 272-5.
15. Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, et al. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 2004; 38 : 1266-72.
16. Avlonitis N, Lekka E, Detsi A, Koufaki M, Calogeropoulou T, Scoulica E, et al. Antileishmanial ring-substituted ether phospholipids. J Med Chem 2003; 46 : 755-67.
17. Lux H, Hart DT, Parker PJ, Klenner T. Ether lipid metabolism, GPI anchor biosynthesis, and signal transduction are putative targets for anti-leishmanial alkyl phospholipid analogues. Adv Exp Med Biol 1996; 416 : 201-11.
18. Paris C, Loiseau PM, Bories C, Breard J. Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes. Antimicrob Agents Chemother 2004; 48 : 852-9.
19. Verma NK, Dey CS. Possible mechanism of miltefosine-related death of Leishmania donovani. Antimicrob Agents Chemother 2004; 48 : 3010-5.
20. Lux H, Heise N, Klenner T, Hart D, Opperdoes FR. Ether-lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether - lipid analogues in Leishmania. Mol Biochem Parasitol 2000; 111 : 1-14.
21. Seifert K, Croft SL. In vitro and in vivo interactions between miltefosine and other antileishmanial drugs. Antimicrob Agents Chemother 2006; 50 : 73-9.
22. Maarouf M, Adeline MT, Solignac M, Vautrin D, Robert-Gero M. Development and characterization of paromomycin-resistant Leishmania donovani promastigotes. Parasite 1998; 5 : 167-73.
23. Maarouf M, Lawrence F, Brown S, Robert-Gero M. Biochemical alterations in paromomycin-treated Leishmania donovani promastigotes. Parasitol Res 1997; 83 : 198-202.
24. Maarouf M, Lawrence F, Croft SL, Robert-Gero M. Ribosomes of Leishmania are a target for the aminoglycosides. Parasitol Res 1995; 81 : 421-5.
25. Neal RA, Allen S, McCoy N, Olliaro P, Croft SL. The sensitivity of Leishmania species to aminosidine. J Antimicrob Chemother 1995; 35 : 577-84.
26. Seaman J, Boer C, Wilkinson R, de Jong J, de Wilde E, Sondorp E. Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions." Clin Infect Dis 1995; 21 : 188-93.
27. Thakur CP, Kanyok TP, Pandey AK, Sinha GP, Zaniewski AE, Houlihan HH, et al. A prospective, randomised, comparative, open-label trial of the safety and efficacy of paromomycin (ammosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis. Trans R Soc Trop Med Hyg 2000; 94 : 429-31.
28. El-On J, Jacobs GP, Witztum E, Greenblatt C. Development of topical treatment for cutaneous leishmaniasis caused by Leishmania major in experimental animals. Antimicrob Agents Chemother 1984; 26 : 745-51.
29. El-On J, Halevy S, Grunwald MH, Weinrauch L. Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: a double-blind control study. J Am Acad Dermatol 1992; 27 : 227-31.
30. Soto JM, Toledo JT, Gutierrez P, Arboleda M, Nicholls RS, Padilla JR, et al. Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot study. Am J Trop Med Hyg 2002; 66 : 147-51.
31. Iraji F, Sadeghinia A. Efficacy of paromomycin ointment in the treatment of cutaneous leishmaniasis: results of a double-blind, randomized trial in Isfahan, Iran. Ann Trop Med Parasitol 2005; 99 : 3-9.
32. Garnier TS, Croft SL. Topical treatment for cutaneous leishmaniasis. Curr Opin Investig Drugs 2002; 3 : 538-44.
33. Meyerhoff A. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis 1999; 28 : 42-8; discussion 49-51.
34. Robinson RF, Nahata MC. A comparative review of conventional and lipid formulations of amphotericin B. J Clin Pharm Ther 1999; 24 : 249-57.
35. Murray HW. Progress in the treatment of a neglected infectious disease: visceral leishmaniasis. Expert Rev Anti Infect Ther 2004; 2 : 279-92.
36. Falk R, Domb AJ, Polacheck I. A novel injectable water-soluble amphotericin B-arabinogalactan conjugate. Antimicrob Agents Chemother 1999; 43 : 1975-81.
37. Golenser J, Frankenburg S, Ehrenfreund T, Domb AJ. Efficacious treatment of experimental leishmaniasis with amphotericin B-arabinogalactan water-soluble derivatives. Antimicrob Agents Chemother 1999; 43 : 2209-14.
38. Espuelas MS, L P, et al. Poly(epsilon-caprolacton) nanospheres as an alternative way to reduce amphotericin B toxicity. Int J Pharmaceutics 1997; 158 : 19-27.
39. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 2000; 50 : 161-77.
40. Larabi M, Yardley V, Loiseau PM, Appel M, Legrand P, Gulik A, et al. Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B. Antimicrob Agents Chemother 2003; 47 : 3774-9.
41. Al-Abdely HM, Graybill JR, Bocanegra R, Najvar L, Montalbo E, Regen SL, et al. Efficacies of KY62 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous leishmaniasis and visceral leishmaniasis. Antimicrob Agents Chemother1998; 42 : 2542-8.
42. Petit C, Yardley V, Gaboriau F, Bolard J, Croft SL. Activity of a heat-induced reformulation of amphotericin B deoxycholate (fungizone) against Leishmania donovani. Antimicrob Agents Chemother 1999; 43 : 390-2.
43. Zvulunov A, Cagnano E, Frankenburg S, Barenholz Y, Vardy D. Topical treatment of persistent cutaneous leishmaniasis with ethanolic lipid amphotericin B." Pediatr Infect Dis J 2003; 22 : 567-9.
44. Hartsel SC, Baas B, Bauer E, Foree Jr LT, Kindt K, Preis H, et al. Heat-induced superaggregation of amphotericin B modifies its interaction with serum proteins and lipoproteins and stimulation of TNF-alpha. J Pharm Sci 2001; 90 : 124-33.
45. Kwong EH, Ramaswamy M, Bauer EA, Hartsel SC, Wasan KM. Heat treatment of amphotericin B modifies its serum pharmacokinetics, tissue distribution, and renal toxicity following administration of a single intravenous dose to rabbits. Antimicrob Agents Chemother 2001; 45 : 2060-3.
46. Lamothe J. A new formulation of Fungizone in the canine model of visceral leishmaniasis: amphotericin B treated by heat. WorldLeish3, Sicily, Italy; 2005.
47. Amato VS, Rabello A, Rotondo-Silva A, Kono A, Maldonado TP, Alves IC, et al. Successful treatment of cutaneous leishmaniasis with lipid formulations of amphotericin B in two immunocompromised patients. Acta Trop 2004; 92 : 127-32.
48. Yardley V, Croft SL. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis. Int J Antimicrob Agents 2000; 13 : 243-8.
49. Yeates C. Sitamaquine (GlaxoSmithKline/Walter Reed Army Institute). Curr Opin Investig Drugs 2002; 3 : 1446-52.
50. Dietze R, Carvalho SF, Valli LC, Berman J, Brewer T, Milhous W, et al. Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi. Am J Trop Med Hyg 2001; 65 : 685-9.
51. Wasunna MK, Rashid JR, Mbui J, Kirigi G, Kinoti D, Lodenyo H, et al. A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya. Am J Trop Med Hyg 2005; 73 : 871-6.
52. Jha TK, Sundar S, Thakur CP, Felton MJ, Sabin AJ, Horton J. A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India. Am J Trop Med Hyg 2005; 73 : 1005-11.
53. Buates S, Matlashewski G. Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action. J Infect Dis 1999; 179 : 1485-94.
54. Arevalo I, Ward B, Miller R, Meng TC, Najar E, Alvarez E, et al. Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of Imiquimod, an immunomodulator. Clin Infect Dis 2001; 33 : 1847-51.
55. Bogdan C, Donhauser N, Doring R, Rollinghoff M, Diefenbach A, Ritting MG. Fibroblasts as host cells in latent leishmaniosis. J Exp Med 2000; 191 : 2121-30.
56. Nicolas L, Sidjanski S, Colle JH, Milon G. Leishmania major reaches distant cutaneous sites where it persists transiently while persisting durably in the primary dermal site and its draining lymph node: a study with laboratory mice. Infect Immun 2000; 68 : 6561-6.
57. Zhai L, Chen M, Blom J, Theander TG, Christensen SB, Kharazmi A. The antileishmanial activity of novel oxygenated chalcones and their mechanism of action. J Antmicrob Chemother 1999; 43 : 793-803.
58. Maes L, Berghe DV, Germonprez N, Quirijnen L, Cos P, De Kimpe N, et al. In vitro and in vivo activities of a triterpenoid saponin extract (PX-6518) from the plant Maesa balansae against visceral Leishmania species. Antimicrob Agents Chemother 2004; 48 : 130-6.
59. Maes L, Germonprez N, Quirijnen L, Van Puyvelde L, Cos P, Vanden Berghe D. Comparative activities of the triterpene saponin Maesabalide III and liposomal amphotericin B (AmBisome) against Leishmania donovani in hamsters. Antimicrob Agents Chemother 2004; 48 : 2056-60.
60. Germonprez N, Maes L, Van Puyvelde L, Van Tri M, Tuan DA, De Kimpe N. In vitro and in vivo anti-leishmanial activity of triterpenoid saponins isolated from Maesa balansae and some chemical derivatives. J Med Chem 2005; 48 : 32-7.
61. Fournet A, Ferreira ME, Rojas De Arias A, Torres De Ortiz A, Fuentes S, Nakayama H, et al. In vivo efficacy of oral and intralesional administration of 2- substituted quinolines in experimental treatment of new world cutaneous leishmaniasis caused by Leishmania amazonensis. Antimicrob Agents Chemother 1996; 40 : 2447-51.
62. Franck X, Fournet A, Prina E, Mahieux R, Hocquemiller R, Figadere B. Biological evaluation of substituted quinolines. Bioorg Med Chem Lett 2004; 14 : 3635-8.
63. Chakrabarti G, Basu A, Manna PP, Mahato SB, Mandal NB, Bandyopadhyay S. Indolylquinoline derivatives are cytotoxic to Leishmania donovani promastigotes and amastigotes in vitro and are effective in treating murine visceral leishmaniasis. J Antimicrob Chemother 1999; 43 : 359-66.
64. Navin TR, Arana BA, Arana FE, Berman JD, Chajon JF. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis 1992; 165 : 528-34.
65. Al-Abdely HM, Graybill JR, Loebenberg D, Melby PC. Efficacy of the triazole SCH 56592 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous and visceral leishmaniases. Antimicrob Agents Chemother 1999; 43 : 2910-4.
66. Rodriguez N, Bailey BN, Martin MB, Oldfield E, Urbina JA, Docampo R. Radical cure of experimental cutaneous leishmaniasis by the bisphosphonate pamidronate. J Infect Dis 2002; 186 : 138-40.
67. Yardley V, Khan AA, Martin MB, Slifer TR, Araujo FG, Moreno SN, et al. In vivo activities of farnesyl pyrophosphate synthase inhibitors against Leishmania donovani and Toxoplasma gondii. Antimicrob Agents Chemother 2002; 46 : 929-31.
68. Nwaka S, Ridley RG. Virtual drug discovery and development for neglected diseases through public-private partnerships. Nat Rev Drug Discov 2003; 2 : 919-28.
69. Croft SL. In vitro screens in the experimental chemotherapy of leishmaniasis and trypanosomiasis. Parasitol Today 1986; 2 : 64-9.
70. Neal RA. Leishmania major: culture media, mouse strains, and promastigote virulence and infectivity. Exp Parasitol 1984; 57 : 269-73.
71. Carrio J, de Colmenares M, Riera C, Gallego M, Arboix M, Portus M. Leishmania infantum: stage-specific activity of pentavalent antimony related with the assay conditions. Exp Parasitol 2000; 95 : 209-14.
72. Agnew P, Holzmuller P, Michalakis Y, Sereno D, Lemesre JL, Renaud F. In vitro growth of Leishmania amazonensis promastigotes resistant to pentamidine is dependent on interactions among strains. Antimicrob Agents Chemother 2001; 45 : 1928-9.
73. Neal RA, Croft SL. An in vitro system for determining the activity of compounds against the intracellular amastigote form of Leishmania donovani. J Antimicrob Chemother 1984; 14 : 463-75.
74. Tempone AG, Perez D, Rath S, Vilarinho AL, Mortara RA, de Andrade HF. Targeting Leishmania (L.) chagasi amastigotes through macrophage scavenger receptors: the use of drugs entrapped in liposomes containing phosphatidylserine. J Antimicrob Chemother 2004; 54 : 60-8.
75. Gebre-Hiwot A, Tadesse G, Croft SL, Frommel D. An in vitro model for screening antileishmanial drugs: the human leukaemia monocyte cell line, THP-1. Acta Trop 1992; 51: 237-45.
76. Carryn S, Van Bambeke F, Mingeot-Leclercq MP, Tulkens PM. Activity of beta-lactams (ampicillin, meropenem), gentamicin, azithromycin and moxifloxacin against intracellular Listeria monocytogenes in a 24 h THP-1 human macrophage model. J Antimicrob Chemother 2003; 51 : 1051-2.
77. Bates PA. Complete developmental cycle of Leishmania mexicana in axenic culture. Parasitology 1994; 108 : 1-9.
78. Callahan HL, Portal AC, Devereaux R, Grogl M. An axenic amastigote system for drug screening. Antimicrob Agents Chemother 1997; 41 : 818-22.
79. Balanco JM, Pral EM, da Silva S, Bijovsky AT, Mortara RA, Alfieri SC. Axenic cultivation and partial characterization of Leishmania braziliensis amastigote-like stages. Parasitology 1998; 116 : 103-13.
80. Sereno D, Lemesre JL. Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents. Antimicrob Agents Chemother 1997; 41 : 972-6.
81. Ephros M, Bitnun A, Shaked P, Waldman E, Zilberstein D. Stage-specific activity of pentavalent antimony against Leishmania donovani axenic amastigotes. Antimicrob Agents Chemother 1999; 43 : 278-82.
82. Sereno D, Holzmuller P, Lemesre JL. Efficacy of second line drugs on antimonyl-resistant amastigotes of Leishmania infantum. Acta Trop 2000; 74 : 25-31.
83. Okuno T, Goto Y, Matsumoto Y, Otsuka H, Matsumoto Y. Applications of recombinant Leishmania amazonensis expressing egfp or the β-galactosidase gene for drug screening and histopathological analysis. Exp Anim 2003; 52 : 109-18.
84. Singh N, Dube A. Short report: fluorescent Leishmania: application to anti-leishmanial drug testing. Am J Trop Med Hyg 2004; 71 : 400-2.
85. Buckner FS, Verlinde CL, La Flamme AC, Van Voorhis WC. Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing β-galactosidase. Antimicrob Agents Chemother 1996; 40 : 2592-7.
86. Lang T, Goyard S, Lebastard M, Milon G. Bioluminescent Leishmania expressing luciferase for rapid and high throughput screening of drugs acting on amastigote-harbouring macrophages and for quantitative real-time monitoring of parasitism features in living mice. Cell Microbiol 2005; 7 : 383-92.
87. Marshall BG, Kropf P, Murray K, Clark C, Flanagan AM, Favidson RN, et al. Bronchopulmonary and mediastinal leishmaniasis: An unusual clinical presentation of Leishmania donovani infection. Clin Infect Dis 2000; 30 : 764-9.
88. Escobar P, Yardley V, Croft SL. Activities of Hexadecylphosphocholine (Miltefosine), AmBisome, and Sodium Stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid Mice. Antimicrob Agents Chemother 2001; 45 : 1872-5.
89. Singh S, Dey A, Sivakumar R. Applications of molecular methods for Leishmania control. Expert Rev Mol Diagn 2005; 5 : 251-65.
90. Yardley V, Croft SL. Animal models of cutaneous leishmaniasis. In: Handbook of animal models of infection. Zak O, editor. New York London: Academic Press; 1999 p. 775-81.
91. Samuelson J, Lerner E, Tesh R, Titus R. A mouse model of Leishmania braziliensis braziliensis infection produced by coinjection with sand fly saliva. J Exp Med 1991; 173 : 49-54.
92. Andrade SG, Carneiro Filho A, de Souza AJ, de Lima ES, Andrade ZA. Influence of treatment with immunosuppressive drugs in mice chronically infected with Trypanosoma cruzi. Int J Exp Pathol 1997; 78 : 391-9.
93. Bretagne S, Durand R, Olivi M, Garin JF, Sulahian A, Rivollet D, et al. Real-time PCR as a new tool for quantifying Leishmania infantum in liver in infected mice. Clin Diagn Lab Immunol 2001; 8 : 828-31.
94. Nicolas L, Prina E, Lang T, Milon G. Real-time PCR for detection and quantitation of Leishmania in mouse tissues. J Clin Microbiol 2002; 40 : 1666-9.
95. Goncalves GS, Fernandes AP, Souza RC, Cardoso JE, de Olivira-Silva F, Maciel FC, et al. Activity of a paromomycin hydrophilic formulation for topical treatment of infections by Leishmania (Leishmania) amazonensis and Leishmania (Vianna) braziliensis. Acta Trop 2005; 93 : 161-7.